VAXESS TECHNOLOGIES AWARDED NSF AND NIH GRANTS FOR DEVELOPMENT OF INNOVATIVE SILK PROTEIN TECHNOLOGY
Funding will advance development of heat-stable rotavirus and polio vaccines and innovative presentation formats
CAMBRIDGE, Massachusetts—April 6th, 2015—Vaxess Technologies, Inc., an innovative life sciences company developing a novel silk protein-based vaccine technology, was awarded two separate Phase I Small Business Innovation Research Grants (SBIR) from the National Science Foundation (NSF) and the National Institute of Health (NIH). Funding totaling $360,000 will go toward the development of novel heat-stable rotavirus and polio vaccines and advancement of innovative vaccine presentation formats.
The highly competitive SBIR program encourages companies to engage in research and development to explore their technological potential and provides the incentive to advance technologies toward commercialization. By targeting small businesses involved in R&D, the program seeks to stimulate high-tech innovation and help the United States meet its specific research and development needs.
“The choice of polio and rotavirus vaccines as the targets for these two government-funded projects is based on Vaxess’s strong focus on advancing global health,” said Vaxess Vice President of Policy and Strategy Livio Valenti. “Coupling thermal stability with ease of administration is a powerful combination to bring vaccines to the people who need them most.”
About Vaxess Technologies
Founded in Boston, Massachusetts in 2012, Vaxess Technologies is pioneering a novel and proprietary vaccine technology based on silk proteins. For more information please visit the company website at www.vaxess.com or send additional inquiries to [email protected].
